Literature DB >> 16908975

Mitochondria in amyotrophic lateral sclerosis: a trigger and a target.

Luc Dupuis1, Jose-Luis Gonzalez de Aguilar, Hugues Oudart, Marc de Tapia, Luis Barbeito, Jean-Philippe Loeffler.   

Abstract

Strong evidence shows that mitochondrial dysfunction is involved in amyotrophic lateral sclerosis (ALS), but despite the fact that mitochondria play a central role in excitotoxicity, oxidative stress and apoptosis, the intimate underlying mechanism linking mitochondrial defects to motor neuron degeneration in ALS still remains elusive. Morphological and functional abnormalities occur in mitochondria in ALS patients and related animal models, although their exact nature and extent are controversial. Recent studies postulate that the mislocalization in mitochondria of mutant forms of copper-zinc superoxide dismutase (SOD1), the only well-documented cause of familial ALS, may account for the toxic gain of function of the enzyme, and hence induce motor neuron death. On the other hand, mitochondrial dysfunction in ALS does not seem to be restricted only to motor neurons as it is also present in other tissues, particularly the skeletal muscle. The presence of this 'systemic' defect in energy metabolism associated with the disease is supported in skeletal muscle tissue by impaired mitochondrial respiration and overexpression of uncoupling protein 3. In addition, the lifespan of transgenic mutant SOD1 mice is increased by a highly energetic diet compensating both the metabolic defect and the motorneuronal function. In this review, we will focus on the mitochondrial dysfunction linked to ALS and the cause-and-effect relationships between mitochondria and the pathological mechanisms thought to be involved in the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16908975     DOI: 10.1159/000085063

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  52 in total

1.  Secreted VAPB/ALS8 major sperm protein domains modulate mitochondrial localization and morphology via growth cone guidance receptors.

Authors:  Sung Min Han; Hiroshi Tsuda; Youfeng Yang; Jack Vibbert; Pauline Cottee; Se-Jin Lee; Jessica Winek; Claire Haueter; Hugo J Bellen; Michael A Miller
Journal:  Dev Cell       Date:  2012-01-19       Impact factor: 12.270

2.  Zinc regulates the stability of repetitive minisatellite DNA tracts during stationary phase.

Authors:  Maire K Kelly; Peter A Jauert; Linnea E Jensen; Christine L Chan; Chinh S Truong; David T Kirkpatrick
Journal:  Genetics       Date:  2007-12       Impact factor: 4.562

3.  Early ALS-type gait abnormalities in AMP-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease.

Authors:  Maxime Vergouts; Claudia Marinangeli; Caroline Ingelbrecht; Geraldine Genard; Olivier Schakman; Anthony Sternotte; André-Guilhem Calas; Emmanuel Hermans
Journal:  Metab Brain Dis       Date:  2015-07-09       Impact factor: 3.584

4.  Mutation Screening of the CHCHD10 Gene in Chinese Patients with Amyotrophic Lateral Sclerosis.

Authors:  QingQing Zhou; YongPing Chen; QianQian Wei; Bei Cao; Ying Wu; Bi Zhao; RuWei Ou; Jing Yang; XuePing Chen; Shinji Hadano; Hui-Fang Shang
Journal:  Mol Neurobiol       Date:  2016-04-07       Impact factor: 5.590

5.  Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency.

Authors:  Kambiz N Alavian; Steven I Dworetzky; Laura Bonanni; Ping Zhang; Silvio Sacchetti; Maria A Mariggio; Marco Onofrj; Astrid Thomas; Hongmei Li; Jamie E Mangold; Armando P Signore; Ulrike Demarco; Damon R Demady; Panah Nabili; Emma Lazrove; Peter J S Smith; Valentin K Gribkoff; Elizabeth A Jonas
Journal:  Brain Res       Date:  2012-01-28       Impact factor: 3.252

6.  Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.

Authors:  Beatrice A Golomb; Abril Verden; Alexis K Messner; Hayley J Koslik; Keith B Hoffman
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

7.  Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis.

Authors:  Yi Zhang; Anna Cook; Jinho Kim; Sergei V Baranov; Jiying Jiang; Karen Smith; Kerry Cormier; Erik Bennett; Robert P Browser; Arthur L Day; Diane L Carlisle; Robert J Ferrante; Xin Wang; Robert M Friedlander
Journal:  Neurobiol Dis       Date:  2013-03-26       Impact factor: 5.996

8.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

9.  Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons.

Authors:  Luc Dupuis; Jose-Luis Gonzalez de Aguilar; Andoni Echaniz-Laguna; Judith Eschbach; Frédérique Rene; Hugues Oudart; Benoit Halter; Caroline Huze; Laurent Schaeffer; Frédéric Bouillaud; Jean-Philippe Loeffler
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

10.  Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis.

Authors:  Luis B Tovar-Y-Romo; Luz Diana Santa-Cruz; Ricardo Tapia
Journal:  Mol Neurodegener       Date:  2009-07-20       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.